Evaluation of risk factors for 14-day and 30-day mortality among treatment regimens against Pseudomonas aeruginosa resistant to carbapenem but susceptible to traditional antipseudomonal non-carbapenem β-lactam agents.
Pseudomonas aeruginosa associated with hospital-acquired infection is often resistant to various antibiotics and is associated with high mortality worldwide. The appropriate treatment of Pseudomonas aeruginosa resistant to carbapenems but susceptible to traditional antipseudomonal non-carbapenem β-l...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2024-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0313944 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850236490477469696 |
|---|---|
| author | Suvadee Supreeyasakon Jantima Traipattanakul Jatapat Hemapanpairoa Piraporn Juntanawiwat Wichai Santimaleeworagun |
| author_facet | Suvadee Supreeyasakon Jantima Traipattanakul Jatapat Hemapanpairoa Piraporn Juntanawiwat Wichai Santimaleeworagun |
| author_sort | Suvadee Supreeyasakon |
| collection | DOAJ |
| description | Pseudomonas aeruginosa associated with hospital-acquired infection is often resistant to various antibiotics and is associated with high mortality worldwide. The appropriate treatment of Pseudomonas aeruginosa resistant to carbapenems but susceptible to traditional antipseudomonal non-carbapenem β-lactam agents (Car-R/NonCar-S P. aeruginosa) remains unclear. This retrospective study evaluated risk factors for 14-day and 30-day mortality among treatment regimens against Car-R/NonCar-S P. aeruginosa. This study enrolled 180 patients with Car-R/NonCar-S P. aeruginosa infection at Phramongkutklao Hospital between January 2019 and December 2023. The 14-day and 30-day mortality rates were 18.3% and 28.9%, respectively. Bloodstream infection (OR 1.97, 95% CI 0.88-4.43), septic shock (OR 3.3, 95% CI 1.30-8.40), Acute Physiology and Chronic Health Evaluation (APACHE) II < 14 (OR 0.13, 95% CI 0.03-0.54), Sequential Organ Failure Assessment (SOFA) <7 (OR 0.25, 95% CI 0.11-0.56), and Pitt bacteremia score <4 (OR 0.16, 95% CI 0.05-0.47) were associated with 14-day mortality. There was a higher 14-day and 30-day mortality in patients treated with piperacillin/tazobactam or aminoglycosides but there was no significant difference among antipseudomonal antimicrobial agents in the treatment of Car-R/NonCar-S P. aeruginosa infection. We supported the use of traditional antipseudomonal β-lactam agents to treat Car-R/NonCar-S P. aeruginosa infections, however the use of piperacillin/tazobactam might be concerned in some cases and further investigations were needed. |
| format | Article |
| id | doaj-art-36f5b8c05fa8440eb2ecd8e7b72fde54 |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-36f5b8c05fa8440eb2ecd8e7b72fde542025-08-20T02:01:57ZengPublic Library of Science (PLoS)PLoS ONE1932-62032024-01-011911e031394410.1371/journal.pone.0313944Evaluation of risk factors for 14-day and 30-day mortality among treatment regimens against Pseudomonas aeruginosa resistant to carbapenem but susceptible to traditional antipseudomonal non-carbapenem β-lactam agents.Suvadee SupreeyasakonJantima TraipattanakulJatapat HemapanpairoaPiraporn JuntanawiwatWichai SantimaleeworagunPseudomonas aeruginosa associated with hospital-acquired infection is often resistant to various antibiotics and is associated with high mortality worldwide. The appropriate treatment of Pseudomonas aeruginosa resistant to carbapenems but susceptible to traditional antipseudomonal non-carbapenem β-lactam agents (Car-R/NonCar-S P. aeruginosa) remains unclear. This retrospective study evaluated risk factors for 14-day and 30-day mortality among treatment regimens against Car-R/NonCar-S P. aeruginosa. This study enrolled 180 patients with Car-R/NonCar-S P. aeruginosa infection at Phramongkutklao Hospital between January 2019 and December 2023. The 14-day and 30-day mortality rates were 18.3% and 28.9%, respectively. Bloodstream infection (OR 1.97, 95% CI 0.88-4.43), septic shock (OR 3.3, 95% CI 1.30-8.40), Acute Physiology and Chronic Health Evaluation (APACHE) II < 14 (OR 0.13, 95% CI 0.03-0.54), Sequential Organ Failure Assessment (SOFA) <7 (OR 0.25, 95% CI 0.11-0.56), and Pitt bacteremia score <4 (OR 0.16, 95% CI 0.05-0.47) were associated with 14-day mortality. There was a higher 14-day and 30-day mortality in patients treated with piperacillin/tazobactam or aminoglycosides but there was no significant difference among antipseudomonal antimicrobial agents in the treatment of Car-R/NonCar-S P. aeruginosa infection. We supported the use of traditional antipseudomonal β-lactam agents to treat Car-R/NonCar-S P. aeruginosa infections, however the use of piperacillin/tazobactam might be concerned in some cases and further investigations were needed.https://doi.org/10.1371/journal.pone.0313944 |
| spellingShingle | Suvadee Supreeyasakon Jantima Traipattanakul Jatapat Hemapanpairoa Piraporn Juntanawiwat Wichai Santimaleeworagun Evaluation of risk factors for 14-day and 30-day mortality among treatment regimens against Pseudomonas aeruginosa resistant to carbapenem but susceptible to traditional antipseudomonal non-carbapenem β-lactam agents. PLoS ONE |
| title | Evaluation of risk factors for 14-day and 30-day mortality among treatment regimens against Pseudomonas aeruginosa resistant to carbapenem but susceptible to traditional antipseudomonal non-carbapenem β-lactam agents. |
| title_full | Evaluation of risk factors for 14-day and 30-day mortality among treatment regimens against Pseudomonas aeruginosa resistant to carbapenem but susceptible to traditional antipseudomonal non-carbapenem β-lactam agents. |
| title_fullStr | Evaluation of risk factors for 14-day and 30-day mortality among treatment regimens against Pseudomonas aeruginosa resistant to carbapenem but susceptible to traditional antipseudomonal non-carbapenem β-lactam agents. |
| title_full_unstemmed | Evaluation of risk factors for 14-day and 30-day mortality among treatment regimens against Pseudomonas aeruginosa resistant to carbapenem but susceptible to traditional antipseudomonal non-carbapenem β-lactam agents. |
| title_short | Evaluation of risk factors for 14-day and 30-day mortality among treatment regimens against Pseudomonas aeruginosa resistant to carbapenem but susceptible to traditional antipseudomonal non-carbapenem β-lactam agents. |
| title_sort | evaluation of risk factors for 14 day and 30 day mortality among treatment regimens against pseudomonas aeruginosa resistant to carbapenem but susceptible to traditional antipseudomonal non carbapenem β lactam agents |
| url | https://doi.org/10.1371/journal.pone.0313944 |
| work_keys_str_mv | AT suvadeesupreeyasakon evaluationofriskfactorsfor14dayand30daymortalityamongtreatmentregimensagainstpseudomonasaeruginosaresistanttocarbapenembutsusceptibletotraditionalantipseudomonalnoncarbapenemblactamagents AT jantimatraipattanakul evaluationofriskfactorsfor14dayand30daymortalityamongtreatmentregimensagainstpseudomonasaeruginosaresistanttocarbapenembutsusceptibletotraditionalantipseudomonalnoncarbapenemblactamagents AT jatapathemapanpairoa evaluationofriskfactorsfor14dayand30daymortalityamongtreatmentregimensagainstpseudomonasaeruginosaresistanttocarbapenembutsusceptibletotraditionalantipseudomonalnoncarbapenemblactamagents AT pirapornjuntanawiwat evaluationofriskfactorsfor14dayand30daymortalityamongtreatmentregimensagainstpseudomonasaeruginosaresistanttocarbapenembutsusceptibletotraditionalantipseudomonalnoncarbapenemblactamagents AT wichaisantimaleeworagun evaluationofriskfactorsfor14dayand30daymortalityamongtreatmentregimensagainstpseudomonasaeruginosaresistanttocarbapenembutsusceptibletotraditionalantipseudomonalnoncarbapenemblactamagents |